Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Breast Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
48 drugs · 217 active trials
17 drugs · 330 active trials
43 drugs · 1,254 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 16 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Fludarabine | Phase 2 | Phase 2 | 10 | 8 | 0 | 32 | 0 | — | — | 1998-01 |
| Ipilimumab | Phase 2 | Phase 2 | 10 | 3 | 0 | 23 | 0 | — | — | 2003-04 |
| Patritumab Deruxtecan | Phase 2 | Phase 2 | 5 | 4 | 0 | 9 | 0 | — | — | Nov 28, 2016 |
| Leucovorin | Phase 2 | Phase 2 | 4 | 2 | 0 | 16 | 0 | — | — | 1996-02 |
| Oxaliplatin | Phase 2 | Phase 2 | 4 | 2 | 0 | 16 | 0 | — | — | 2000-05 |
| Cemiplimab | Phase 2 | Phase 2 | 4 | 3 | 0 | 8 | 0 | — | — | Mar 1, 2010 |
| Binimetinib | Phase 2 | Phase 2 | 4 | 2 | 0 | 6 | 0 | — | — | Aug 17, 2015 |
| Cetuximab | Phase 2 | Phase 2 | 3 | 2 | 0 | 16 | 0 | — | — | 2005-11 |
| Ruxolitinib | Phase 2 | Phase 2 | 3 | 2 | 0 | 11 | 0 | — | — | 2012-06 |
| Copanlisib | Phase 2 | Phase 2 | 3 | 0 | 0 | 10 | 0 | — | — | Aug 17, 2015 |
| Selumetinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 10 | 0 | — | — | Dec 14, 2007 |
| Tislelizumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 9 | 0 | — | — | Mar 23, 2020 |
| Cabozantinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 8 | 0 | — | — | 2011-10 |
| Cediranib | Phase 2 | Phase 2 | 3 | 1 | 0 | 8 | 0 | — | — | 2005-09 |
| Hydroxychloroquine | Phase 2 | Phase 2 | 3 | 1 | 0 | 8 | 0 | — | — | 2009-02 |
| Dostarlimab | Phase 2 | Phase 2 | 3 | 0 | 0 | 3 | 0 | — | — | Jan 21, 2021 |
| Vorinostat | Phase 2 | Phase 2 | 2 | 0 | 0 | 18 | 0 | — | — | 2005-06 |
| Bortezomib | Phase 2 | Phase 2 | 2 | 2 | 0 | 10 | 0 | — | — | 2001-05 |
| Temozolomide | Phase 2 | Phase 2 | 2 | 0 | 0 | 10 | 0 | — | — | 1998-05 |
| Alisertib | Phase 2 | Phase 2 | 2 | 1 | 0 | 9 | 0 | — | — | 2010-02 |
| Panitumumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 7 | 0 | — | — | 2010-02 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | 1996-02 |
| Vistusertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 4 | 0 | — | — | May 8, 2012 |
| Osimertinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Tretinoin | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Apr 1, 2020 |
| Fexagratinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Apr 7, 2014 |
| Zongertinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jun 28, 2024 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 19 | 0 | — | — | 2006-12 |
| Tremelimumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 10 | 0 | — | — | 2010-07 |
| Cobimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | Mar 12, 2015 |
| Vandetanib | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | 2006-01 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | 2012-05 |
| Ganetespib | Phase 2 | Phase 2 | 1 | 1 | 0 | 6 | 0 | — | — | Mar 1, 2010 |
| Entrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | Nov 19, 2015 |
| Romidepsin | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2005-02 |
| Sintilimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | 2021-03 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2009-11 |
| Afimoxifene | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2003-04 |
| Azacitidine | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2011-01 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Feb 13, 2014 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2012-01 |
| Darolutamide | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Jul 23, 2018 |
| Decitabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2001-12 |
| Imatinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2005-05 |
| Selinexor | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Jun 26, 2015 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Degarelix | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 28, 2019 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Ibrutinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2015-03 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.